Go Pro
NYSE:LH

Labcorp (LH) Stock Price, News & Analysis

Labcorp logo
$330.77 +8.59 (+2.67%)
Closing price 08/19/2026 03:59 PM Eastern
Extended Trading
$328.48 -2.28 (-0.69%)
As of 07:19 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Labcorp Stock (NYSE:LH)

Advanced

Key Stats

Today's Range
$323.41
$331.20
50-Day Range
$254.53
$330.77
52-Week Range
$244.52
$331.20
Volume
518,205 shs
Average Volume
759,041 shs
Market Capitalization
$26.83 billion
P/E Ratio
27.36
Dividend Yield
0.87%
Price Target
$330.00
Consensus Rating
Moderate Buy

Company Overview

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services. Its diagnostics offerings include routine and specialty clinical tests, anatomic pathology, molecular and genomic testing, toxicology and companion diagnostics. On the drug development side, the company provides preclinical and clinical research services, central laboratory support, biomarker development, regulatory and commercialization services to pharmaceutical and biotechnology clients.

The company serves a wide range of customers including physicians, hospitals and health systems, biopharmaceutical companies, employers and public health agencies. Labcorp’s operations extend across the United States and into international markets through laboratory facilities, partnerships and service centers, enabling it to support clinical trials and diagnostic needs on a global scale.

Organized to combine diagnostic testing with drug development capabilities, Labcorp has developed integrated service offerings designed to streamline clinical development and accelerate the translation of laboratory findings into clinical and commercial outcomes. As a publicly traded company, it is positioned to leverage laboratory infrastructure, data analytics and scientific expertise to meet evolving needs in healthcare and life sciences.

AI Generated. May Contain Errors.

Labcorp Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
80th Percentile Overall Score

LH MarketRank™: 

Labcorp scored higher than 80% of companies evaluated by MarketBeat, and ranked 116th out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Labcorp has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 9 buy ratings, 3 hold ratings, and no sell ratings.

  • Upside/Downside

    The consensus price target for Labcorp is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Labcorp has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Labcorp's stock forecast and price target.
  • Earnings Growth

    Earnings for Labcorp are expected to grow by 7.31% in the coming year, from $18.32 to $19.66 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Labcorp is 27.36, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.61.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Labcorp is 27.36, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 268.96.

  • Price to Earnings Growth Ratio

    Labcorp has a PEG Ratio of 1.86. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Labcorp has a P/B Ratio of 3.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Labcorp's valuation and earnings.
  • Percentage of Shares Shorted

    2.60% of the float of Labcorp has been sold short.
  • Short Interest Ratio / Days to Cover

    Labcorp has a short interest ratio ("days to cover") of 2.18, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Labcorp has recently decreased by 23.05%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Labcorp has a dividend yield of 0.89%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Labcorp does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Labcorp is 23.82%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Labcorp will have a dividend payout ratio of 14.65% next year. This indicates that Labcorp will be able to sustain or increase its dividend.

  • Read more about Labcorp's dividend.
  • News Sentiment

    Labcorp has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Labcorp this week, compared to 5 articles on an average week.
  • Search Interest

    Only 3 people have searched for LH on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Labcorp to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Labcorp insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,027,677.00 in company stock.

  • Percentage Held by Insiders

    0.84% of the stock of Labcorp is held by insiders.

  • Percentage Held by Institutions

    95.94% of the stock of Labcorp is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Labcorp's insider trading history.
Receive LH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Labcorp and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LH Stock News Headlines

Labcorp to Host Investor Day on September 10, 2026
These 3 Stocks Could Soar as Sam Altman Announces New Venture After OpenAI
Elon Musk calls it the most disruptive force in history. Sam Altman is reportedly preparing a new venture after OpenAI, one some say could be 500 times bigger than ChatGPT. Test staff are said to be bound by law to keep details secret, and three lesser-known stocks may be tied to this next chapter in AI.tc pixel
Amy Summy Sells 924 Shares of Labcorp (NYSE:LH) Stock
See More Headlines

LH Stock Analysis - Frequently Asked Questions

Labcorp's stock was trading at $250.87 on January 1st, 2026. Since then, LH stock has increased by 31.8% and is now trading at $330.7680.

Labcorp Holdings Inc. (NYSE:LH) posted its quarterly earnings results on Thursday, July, 30th. The medical research company reported $4.99 EPS for the quarter, beating the consensus estimate of $4.78 by $0.21. The business's revenue was up 5.8% compared to the same quarter last year.
Read the conference call transcript
.

Labcorp subsidiaries include these companies: Clinical Outreach Laboratory Services, Personal Genome Diagnostics Inc., Toxikon Corporation, Myriad Autoimmune’s Vectra Testing Business, Ovia Health, Visiun, Envigo's nonclinical contract research services business, and others.

Top institutional shareholders of Labcorp include Wellington Management Group LLP (1.05%), Diamond Hill Capital Management LLC Investment Advisor (0.73%), Bank of New York Mellon Corp (0.62%) and Madison Asset Management LLC (0.59%). Insiders that own company stock include Adam H Schechter, Glenn A Eisenberg, Brian J Caveney, Lance Berberian, Amy B Summy, Bryan T Vaughn, Dwight Gary Gilliland, Kerrii B Anderson, Mark S Schroeder, Kathryn W Kyle, Jonathan P Divincenzo, Jonathan C Meltzer, Der Vaart Sandra D Van, Richelle P Parham and Peter J Wilkinson.
View institutional ownership trends
.

Shares of LH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Labcorp investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

Record date for 6/11 Dividend
5/29/2026
Ex-Dividend for 6/11 Dividend
5/29/2026
Dividend Payable
6/11/2026
Last Earnings
7/30/2026
Today
8/20/2026
Record date for 9/11 Dividend
8/28/2026
Ex-Dividend for 9/11 Dividend
8/28/2026
Investor Day 2026
9/10/2026
Dividend Payable
9/11/2026
Next Earnings (Estimated)
10/27/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Healthcare Providers & Services
Sub-Industry
Healthcare Services
Current Symbol
NYSE:LH
Previous Symbol
NYSE:LH?
CIK
920148
Employees
71,000
Year Founded
1995

Price Target and Rating

High Price Target
$360.00
Low Price Target
$300.00
Potential Upside/Downside
-0.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
12 Analysts

Profitability

EPS (Trailing Twelve Months)
$12.09
Trailing P/E Ratio
27.36
Forward P/E Ratio
18.06
P/E Growth
1.86
Net Income
$876.50 million
Net Margins
6.99%
Pretax Margin
8.60%
Return on Equity
16.74%
Return on Assets
7.81%

Debt

Debt-to-Equity Ratio
0.69
Current Ratio
1.80
Quick Ratio
1.53

Sales & Book Value

Annual Sales
$13.95 billion
Price / Sales
1.92
Cash Flow
$25.48 per share
Price / Cash Flow
12.98
Book Value
$106.13 per share
Price / Book
3.12

Miscellaneous

Outstanding Shares
81,100,000
Free Float
80,419,000
Market Cap
$26.83 billion
Optionable
Optionable
Beta
0.87

Social Links

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NYSE:LH) was last updated on 8/20/2026 by MarketBeat.com Staff.
From Our Partners